KRTX - With Karuna Therapeutics $14B Deal Bristol Myers Is Serious For Re-Establishing Its Neurology Portfolio: Analyst | Benzinga
Earlier Friday, Bristol Myers Squibb & Co (NYSE: BMY) agreed to acquire Karuna Therapeutics Inc (NASDAQ: KRTX) for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired.
William Blair highlights Bristol Myers' commitment to reestablishing its neuroscience pipeline as a primary focus during the 2023 R&D event. Management is actively pursuing strategies to counter the forthcoming loss of exclusivities by seeking de-risked assets and demonstrating a willingness to pay significant premiums for such assets.
The analyst says there is a debate on whether the acquisition is ...